骨关节炎生物标志物：现状与展望 - FNIH 生物标志物联盟 PROGRESS OA 研究。

Biomarkers in osteoarthritis: current status and outlook - the FNIH Biomarkers Consortium PROGRESS OA study.

机构信息

Sydney Musculoskeletal Health, Kolling Institute, Faculty of Medicine, University of Sydney, Australia and Rheumatology Department, Royal North Shore Hospital, St Leonards, NSW, 2065, Australia.

Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

出版信息

Skeletal Radiol. 2023 Nov;52(11):2323-2339. doi: 10.1007/s00256-023-04284-w. Epub 2023 Jan 24.

DOI:10.1007/s00256-023-04284-w

PMID:36692532

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10509067/

Abstract

Currently, no disease-modifying therapies are approved for osteoarthritis (OA) use. One obstacle to trial success in this field has been our existing endpoints' limited validity and responsiveness. To overcome this impasse, the Foundation for the NIH OA Biomarkers Consortium is focused on investigating biomarkers for a prognostic context of use for subsequent qualification through regulatory agencies. This narrative review describes this activity and the work underway, focusing on the PROGRESS OA study.

摘要

目前，尚无经批准用于骨关节炎（OA）的疾病修正疗法。该领域临床试验取得成功的一个障碍是现有终点的有效性和反应性有限。为了克服这一困境，美国国立卫生研究院 OA 生物标志物联盟基金会专注于研究预后使用的生物标志物，以便随后通过监管机构进行资格认证。本文叙述性综述介绍了这一活动和正在进行的工作，重点介绍了 PROGRESS OA 研究。